User:Mr. Ibrahem/Tazemetostat

Tazemetostat, sold under the brand name Tazverik, is a medication used to treat epithelioid sarcoma which cannot be removed by surgery and non-Hodgkin lymphoma that has failed other treatments. It is taken by mouth.

Common side effects include pain, tiredness, nausea, decreased appetite, vomiting, and constipation. Other side effects may include secondary cancers including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, and acute myeloid leukemia. It works by blocking the activity of EZH2.

Tazemetostat was approved for medical use in the United States in 2020. As of 2021 has not been fully approved in Europe; though has been granted an orphan designation. In the United States it costs about 17,300 USD per month as of 2021.